What top creators are saying about CVS Caremark(CVS)

Under intense scrutiny regarding PBM drug pricing and rebate structures, though may have fee-based levers to maintain margins.

The stock closed down 14% as a direct result of the Medicare rate news, which poses a direct threat to the profitability of its insurance operations.

Stock 'cratered' due to a proposed Medicare Advantage rate increase of only 0.09%, which is seen as 'incredibly insufficient' to cover rising costs, putting sustained pressure on earnings.

Negatively impacted along with other insurers by a government proposal for nearly flat Medicare Advantage payment rates.

Fell 8% in after-hours trading on news of a proposed Medicare Advantage rule change that negatively impacts the profitability of health insurers.

Presents a balanced view: The 'captive strategy' of vertical integration is a powerful business model and competitive advantage (bull case), but it also faces significant regulatory and political scrutiny risk due to concerns about 'market concentration' (bear case).

Faces a major disruptive threat to its PBM business model from a government policy to move more prescription drugs to over-the-counter status, which would reduce prescription volume and fees.

Took a $5.9 billion write-down on the Oak Street Health acquisition, which is seen as a major strategic blunder. The company also faces significant disruption risk to its core PBM business.

Business model is considered at risk of becoming obsolete due to disruption from telehealth companies like HIMS and e-commerce.

Host expressed a very bearish view, mentioning its subsidiary Aetna as part of an industry considered one of the 'biggest scams in history.' The analysis highlights significant political and regulatory risk from potential policy changes, such as lowering the Medicare eligibility age, which would threaten the private health insurance business model.

Its subsidiary Aetna's exit from the ACA marketplace is seen as a disciplined business decision to shed a low-margin, high-risk segment, reducing the company's exposure to political risks over subsidies.

An agreement to extend ACA subsidies, which is considered likely, would be a bullish catalyst for its Aetna insurance business.

Mentioned as a traditional pharmacy that is struggling as consumers increasingly move to buy medications online.

Faces significant regulatory and business model risk due to widespread negative sentiment towards its Pharmacy Benefit Manager (PBM) division, as highlighted by criticism from pharmaceutical executives.

Considered a less risky peer to UNH, as its value-based care business (Oak Street Health) is only 2% of its enterprise earnings, making the negative impact from the V28 risk model revision much more manageable.

Investors in companies heavily reliant on the current opaque PBM system, such as CVS, should be aware of the growing risk from new transparent competitors and potential government regulation or antitrust action.

Investors can view CVS as a company providing an essential service within the healthcare sector, with its business tied to health insurance plans and prescription drug management, suggesting a potentially stable, non-discretionary demand for its services.